From Concept to PracticeFrom Human Papillomavirus to Cervical CancerSchiffman, Mark MD, MPH; Wentzensen, Nicolas MD, PhDAuthor Information From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland. Corresponding author: Mark Schiffman, MD, MPH, National Cancer Institute, 6120 Executive Blvd, Room 7012, Rockville, MD 20852; e-mail: firstname.lastname@example.org. Financial Disclosure Both authors work with Qiagen to help evaluate the CareHPV test in Africa. There is cost-sharing only. This will not be sold except for public health use in low-resource countries, where it will be sold at a few dollars per test. Dr. Schiffman works with the U.S. Food and Drug Administration as well as the National Cancer Institute (NCI). He is the Medical Monitor of the independent human papillomavirus (HPV) vaccine trial of Cervarix, being conducted by THE NCI, for which he does not receive compensation. GlaxoSmithKline pays costs related to regulatory use of the data. He also works on the development of HPV tests for low-resource public health settings and is collaborating with Qiagen on this effort. Qiagen is providing free test supplies for this research effort but has no role in the evaluation of performance. Obstetrics & Gynecology: July 2010 - Volume 116 - Issue 1 - p 177-185 doi: 10.1097/AOG.0b013e3181e4629f Buy Metrics Virtually all cervical cancers are caused by persistent infections with human papillomaviruses; this article summarizes the scientific advances leading to improved cervical cancer prevention. © 2010 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.